Literature DB >> 18176999

Application of quantitative structure-activity relationships to the modeling of antitubercular compounds. 1. The hydrazide family.

Cristina Ventura1, Filomena Martins.   

Abstract

A QSAR/QSPR methodology was used to analyze a set of 173 hydrazides, a great part of which are isoniazid (INH) derivatives. Nineteen molecular descriptors of various types (physicochemical, steric, geometrical, and electronic) have been systematically tested through a careful application of MLR. The analysis revealed that the biological activity of these compounds against M. tuberculosis does not depend on lipophilicity, as measured by log P. Properties that account for the biological response of isoniazid and related compounds, consistent with a mechanism involving the formation of radical species, were identified. The role of substituents in the stabilization of the intermediate species that gives rise to the active agent, the acyl radical, is discussed. It is postulated that the activation of INH derivatives' prodrugs (hydrazines and hydrazones) occurs near the surface of M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18176999     DOI: 10.1021/jm701048s

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  On the interpretation and interpretability of quantitative structure-activity relationship models.

Authors:  Rajarshi Guha
Journal:  J Comput Aided Mol Des       Date:  2008-09-11       Impact factor: 3.686

2.  Two new atom centered fragment descriptors and scoring function enhance classification of antibacterial activity.

Authors:  Durga Datta Kandel; Chandan Raychaudhury; Debnath Pal
Journal:  J Mol Model       Date:  2014-03-25       Impact factor: 1.810

Review 3.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.

Authors:  Sean Ekins; Joel S Freundlich; Inhee Choi; Malabika Sarker; Carolyn Talcott
Journal:  Trends Microbiol       Date:  2010-12-02       Impact factor: 17.079

4.  (E)-N'-(2-Hydr-oxy-4-methoxy-benzyl-idene)isonicotinohydrazide monohydrate.

Authors:  San-Jun Peng; Hai-Yun Hou
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-09-24

5.  (E)-N'-(4-Hydroxy-benzyl-idene)-2-methoxy-benzohydrazide.

Authors:  Xue-Hui Zhan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-09-24

6.  Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents.

Authors:  Kirk E Hevener; David M Ball; John K Buolamwini; Richard E Lee
Journal:  Bioorg Med Chem       Date:  2008-07-29       Impact factor: 3.641

7.  Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.

Authors:  Michael J Hearn; Michael H Cynamon; Michaeline F Chen; Rebecca Coppins; Jessica Davis; Helen Joo-On Kang; Abigail Noble; Becky Tu-Sekine; Marianne S Terrot; Daniella Trombino; Minh Thai; Eleanor R Webster; Rebecca Wilson
Journal:  Eur J Med Chem       Date:  2009-05-21       Impact factor: 6.514

8.  N'-(5-Bromo-2-hydr-oxy-3-methoxy-benzyl-idene)isonicotinohydrazide.

Authors:  San-Jun Peng; Hai-Yun Hou
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-09-24

9.  A Target-Based Whole Cell Screen Approach To Identify Potential Inhibitors of Mycobacterium tuberculosis Signal Peptidase.

Authors:  Shilah A Bonnett; Juliane Ollinger; Susantha Chandrasekera; Stephanie Florio; Theresa O'Malley; Megan Files; Jo-Ann Jee; James Ahn; Allen Casey; Yulia Ovechkina; David Roberts; Aaron Korkegian; Tanya Parish
Journal:  ACS Infect Dis       Date:  2016-09-19       Impact factor: 5.084

10.  Synthesis, Characterization, and Biologic Activity of New Acyl Hydrazides and 1,3,4-Oxadiazole Derivatives.

Authors:  Irina Zarafu; Lilia Matei; Coralia Bleotu; Petre Ionita; Arnaud Tatibouët; Anca Păun; Ioana Nicolau; Anamaria Hanganu; Carmen Limban; Diana Camelia Nuta; Roxana Maria Nemeș; Carmen Cristina Diaconu; Cristiana Radulescu
Journal:  Molecules       Date:  2020-07-21       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.